The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Research Report 2024
Synopsis
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at US$ 21390 million in 2023 and is anticipated to reach US$ 29810 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
Report Scope
The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at US$ 21390 million in 2023 and is anticipated to reach US$ 29810 million by 2030, witnessing a CAGR of 4.8% during the forecast period 2024-2030.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
Report Scope
The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Segment by Type
Consumables
Services
Software
Segment by Application
Oncology
Cardiology
Neurology
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Consumables
1.2.3 Services
1.2.4 Software
1.3 Market by Application
1.3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Neurology
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2019-2030)
2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Region
2.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Region (2019-2024)
2.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2025-2030)
2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Dynamics
2.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
2.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
2.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
2.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue
3.1.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (2019-2024)
3.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2019-2024)
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue
3.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio
3.4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2023
3.5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Key Players Head office and Area Served
3.6 Key Players Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Solution and Service
3.7 Date of Enter into Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type
4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2019-2024)
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2025-2030)
5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2019-2024)
5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
6.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
6.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
7.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
7.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
8.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2019-2024)
8.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
9.2 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
9.4 Latin America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2019-2030)
10.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2019-2024)
10.4 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.1.4 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Dako (Agilent Technologies)
11.2.1 Dako (Agilent Technologies) Company Detail
11.2.2 Dako (Agilent Technologies) Business Overview
11.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.2.4 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.2.5 Dako (Agilent Technologies) Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.3.4 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.3.5 Merck Recent Development
11.4 BD
11.4.1 BD Company Detail
11.4.2 BD Business Overview
11.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.4.4 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.4.5 BD Recent Development
11.5 Abbott
11.5.1 Abbott Company Detail
11.5.2 Abbott Business Overview
11.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.5.4 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.5.5 Abbott Recent Development
11.6 Genesys Biolabs (20/20GeneSystems)
11.6.1 Genesys Biolabs (20/20GeneSystems) Company Detail
11.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
11.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.6.4 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.6.5 Genesys Biolabs (20/20GeneSystems) Recent Development
11.7 Affymetrix
11.7.1 Affymetrix Company Detail
11.7.2 Affymetrix Business Overview
11.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.7.4 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.7.5 Affymetrix Recent Development
11.8 Agendia
11.8.1 Agendia Company Detail
11.8.2 Agendia Business Overview
11.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.8.4 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.8.5 Agendia Recent Development
11.9 ALMAC
11.9.1 ALMAC Company Detail
11.9.2 ALMAC Business Overview
11.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.9.4 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.9.5 ALMAC Recent Development
11.10 Arrayit
11.10.1 Arrayit Company Detail
11.10.2 Arrayit Business Overview
11.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.10.4 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.10.5 Arrayit Recent Development
11.11 Biocartic
11.11.1 Biocartic Company Detail
11.11.2 Biocartic Business Overview
11.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.11.4 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.11.5 Biocartic Recent Development
11.12 BG Medicine
11.12.1 BG Medicine Company Detail
11.12.2 BG Medicine Business Overview
11.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.12.4 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.12.5 BG Medicine Recent Development
11.13 KEGG EXPRESSION Database
11.13.1 KEGG EXPRESSION Database Company Detail
11.13.2 KEGG EXPRESSION Database Business Overview
11.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.13.4 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.13.5 KEGG EXPRESSION Database Recent Development
11.14 Thermo Fisher
11.14.1 Thermo Fisher Company Detail
11.14.2 Thermo Fisher Business Overview
11.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.14.4 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.14.5 Thermo Fisher Recent Development
11.15 BGI
11.15.1 BGI Company Detail
11.15.2 BGI Business Overview
11.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Introduction
11.15.4 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2019-2024)
11.15.5 BGI Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
